Astigmatism Post-trabeculectomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

52 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this project:

1. Confirming the modification in corneal astigmatism after trabeculectomy with MMC and intracameral administration of bevacizumab.
2. Medium-term follow up (6 months) of the induced corneal astigmatism.
3. Investigating correlations between postoperative astigmatism, particularly with the postoperative IOP.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

glaucoma trabeculectomy astigmatism intraocular pressure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

trabeculectomy

Filtering surgery to reduce the intra-ocular pressure.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary open angle glaucoma
* Normal tension glaucoma
* Pseudoexfoliation glaucoma
* Pigment dispersion glaucoma

Exclusion Criteria

* Patients who refuse to sign the informed consent.
* Patients with primary angle closure glaucoma (PACG).
* Patients younger than 18 years old.
* Other ocular diseases besides glaucoma.
* Significant corneal opacities.
* Refractive error more than + or -6.00 diopters.
* Visual acuity less than 0.05
* Previous intra-ocular surgery (except cataract surgery more than six months preceding the trabeculectomy).
* Laser treatment for glaucoma within 6 months of the surgery.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Heleen Delbeke

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Heleen Delbeke, MD

Role: PRINCIPAL_INVESTIGATOR

UZ Leuven

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sint-Raphaël hospital

Leuven, Vlaams-Brabant, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S53708

Identifier Type: -

Identifier Source: org_study_id